SEB Asset Management AB Buys Shares of 158,205 Arrowhead Pharmaceuticals, Inc. $ARWR

SEB Asset Management AB bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 158,205 shares of the biotechnology company’s stock, valued at approximately $9,919,000.

A number of other large investors also recently modified their holdings of the business. Tsfg LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $25,000. First Horizon Corp acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $32,000. WPG Advisers LLC lifted its holdings in Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 431 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $54,000. 62.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price for the company. Sanford C. Bernstein raised their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Chardan Capital restated a “buy” rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 30th. Leerink Partners boosted their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. Finally, Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.75.

Arrowhead Pharmaceuticals Trading Down 3.6%

Shares of NASDAQ:ARWR opened at $71.65 on Tuesday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The company’s 50-day moving average price is $77.50 and its 200 day moving average price is $69.51. The company has a market cap of $10.09 billion, a PE ratio of -33.33 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $87.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter in the prior year, the firm earned $2.75 EPS. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.07 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 26,065 shares of company stock worth $1,912,662. Company insiders own 3.60% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.